Cerity Partners’s CRISPR Therapeutics CRSP Stock Holding History

Cerity Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Buy	+6,558	New	+$346K	﹤0.01%	2669
2025 Q4	–	Sell	-4,188	Closed	-$271K	–	2903
2025 Q3	$271K	Sell	4,188 -2,353	-36%	-$135K	﹤0.01%	2343
2025 Q2	$318K	Buy	6,541 +190	+3%	+$7.35K	﹤0.01%	2125
2025 Q1	$216K	Buy	+6,351	New	+$269K	﹤0.01%	2182
2022 Q2	–	Sell	-3,818	Closed	-$239K	–	1191
2022 Q1	$239K	Buy	3,818 +9	+0.2%	+$565	﹤0.01%	809
2021 Q4	$289K	Buy	3,809 +1,360	+56%	+$119K	﹤0.01%	780
2021 Q3	$274K	Hold	2,449	–	–	0.01%	583
2021 Q2	$396K	Hold	2,449	–	–	0.01%	516
2021 Q1	$298K	Buy	+2,449	New	+$370K	0.01%	559

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cerity Partners's CRSP Position: Q2 2026 in Review

Cerity Partners opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 6,558 shares worth $358K. The stake represents ﹤0.01% of the portfolio and ranks #2669 among its holdings. This is a return to the name: Cerity Partners previously reported a position in CRSP as recently as Q3 2025.

Cerity Partners first reported a position in CRSP in Q1 2021 and has held it in 9 quarters since. The position peaked at $396K in Q2 2021. 469 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Cerity Partners held 6,558 shares of CRISPR Therapeutics worth $358K as of Q2 2026.
CRISPR Therapeutics was a new Cerity Partners position in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2669 holding.
Cerity Partners first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 9 quarters since.
Cerity Partners's CRISPR Therapeutics position peaked at $396K in Q2 2021.
469 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.